| Abstrakt: |
Researchers at the Tokyo Metropolitan Institute of Medical Science have published new data on hematopoietic stem cells, specifically focusing on the modification of Lhx2 activity for the ex vivo amplification of human iPSC-derived hematopoietic stem/progenitor cells. The study found that while Lhx2 had previously shown promise in generating hematopoietic stem cells from mouse iPSCs, it inhibited the proliferation of human iPSC-derived hematopoietic cells. By modifying Lhx2 to enhance its transcriptional activation ability, researchers were able to induce the ex vivo amplification of human iPSC-derived hematopoietic stem/progenitor cells, potentially advancing the development of methods to efficiently produce HSCs from human iPSCs. [Extracted from the article] |
